|Bid||185.66 x 800|
|Ask||185.84 x 1100|
|Day's Range||185.26 - 187.83|
|52 Week Range||176.36 - 242.99|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||17.76|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||258.59|
Healthcare stocks are trailing the market since the start of the pandemic. Barron's looked for those at the biggest discounts to the average price targets among analysts.
Vertex Pharmaceuticals' (NASDAQ: VRTX) woes began about a year ago when it announced the failure of an alpha-1 antitrypsin deficiency (AATD) candidate in clinical trials. Since that first problem, Vertex shares have dropped 33%. Vertex boasts a billion-dollar cystic fibrosis (CF) business.
Vertex Pharmaceuticals (NASDAQ: VRTX) is one of the largest biopharma businesses in the world, but you've probably never heard of anyone taking the medications that it makes. Today, Vertex's shares go for around $180. Right now, Vertex has four drugs that are approved for sale, all of which are combinations of molecules it developed to treat cystic fibrosis (CF).